Propeller taps MIR to add spirometers to respiratory disease management platform

Propeller app and sensor
Propeller sensor and app--Courtesy of Propeller Health

Propeller Health is teaming up with Medical International Research to integrate a number of MIR’s mobile and clinical spirometers into its digital respiratory disease management platform.

Propeller’s system includes a sensor that attaches to a range of different inhalers to track when, where and why patients take their medication. This information is communicated via Bluetooth to a smartphone app, which uses machine learning to help patients and physicians manage respiratory disease. Integrating spirometers into the system would allow physicians to see spirometry data alongside this information, making it easier for them to check if a patient with asthma or COPD is responding to treatment.

“Periodic assessment can be helpful in monitoring whether treatment is truly controlling symptoms and improving quality of life,” said Propeller CEO David Van Sickle in the statement. “These next-generation, mobile spirometers make it possible for patients to better understand their lung function at home and in the community.”


Like this story? Subscribe to FierceBiotech!

Biopharma is a fast-growing world where big ideas come along every day. Our subscribers rely on FierceBiotech as their must-read source for the latest news, analysis and data in the world of biotech and pharma R&D. Sign up today to get biotech news and updates delivered to your inbox and read on the go.

Spirometry is already used to monitor respiratory disease patients and assess whether their disease is progressing or if their treatment is working. The integration of “several” MIR spirometers into Propeller’s platform will allow for the automatic transmission of data from these devices to the platform. Healthcare providers and pharma partners that use Propeller may now include MIR spirometers in their treatment programs, the company said in the statement.

Propeller has inked no fewer than 45 commercial partnerships around its system in the U.S. One of its partners is GlaxoSmithKline: the pair teamed up last December to develop a custom sensor for the British pharma’s Ellipta inhaler. The FDA cleared the use of Propeller’s tech with Ellipta last month. In February, Propeller joined forces with Aptar Pharma to develop a "smart inhaler," where the sensors are integrated into the device rather than being an add-on. And, having bagged a $21.5 million Series C in October, Propeller is planning on adding yet more pharma and commercial partnerships to its stable.

Suggested Articles

By employing heart rate signals, physical activity and sleep quality, common Fitbit trackers may be able to predict the spread of the flu.

Nanox has raised $26 million to help fuel the development and commercialization of its Star Trek-inspired digital X-ray bed.

Oncology is clearly a major medical and societal issue, but one that sees too much focus from biopharmas at the expense of other killers.